InvestorsHub Logo
Followers 12
Posts 1102
Boards Moderated 0
Alias Born 01/27/2017

Re: skitahoe post# 199

Monday, 01/04/2021 3:57:28 PM

Monday, January 04, 2021 3:57:28 PM

Post# of 249
Yes that is the news that has created such excitement. The link contains the following info posted by the CEO David Goren. The "$1.3 million cash and cash equivalents" is more than the cash that I thought they had, but then again I don't know what the "equivalents" refers to.

This stock was recommended to me by MjMilo and bought a bunch over a year ago. Fortunately I kept a few. Still puzzled why it hasn't received more attention on this board. But maybe that's a good thing!

GLTY. I hope you have a great year!

VAXIL’S ANNUAL AND SPECIAL SHAREHOLDERS MEETING AND UPDATE ON EXERCISE OF WARRANTS
Posted on January 2, 2021 by David Goren
02
JAN
Not for distribution by US newswire or in United States

NESS-ZIONA, ISRAEL – December 31, 2020 – VAXIL BIO LTD. (“VAXIL” or the “COMPANY”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that at the Company’s Annual and Special General Meeting, held on December 30, 2020 in Toronto, all resolutions were duly passed by shareholders.

The Company also announces that since November 26, 2020, the date of the filing of our condensed consolidated interim financial statements for the nine months ended September 30, 2020, we have received aggregate proceeds of $115,000 from the exercise of previously issued (January 2018) warrants, having an exercise price of $0.10 per warrant.

As of December 30, 2020, the Company has $1.3 million in cash and cash equivalents.